Endogenex, a company focused on developing medical devices for type 2 diabetes management, has shared results from its REGENT-1 clinical study during the Digestive Disease Week (DDW) 2025 event held ...

MINNEAPOLIS, May 03, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), presented significant ...

Endogenex has raised $50 million in venture capital financing to complete the development of its minimally invasive procedure for Type 2 diabetes and bring its tech to the FDA. The fundraising comes ...

Endogenex has raised $50m in funding, setting the company up with sufficient funds to complete a pivotal trial of its type 2 diabetes (T2D) treatment and support a regulatory filing for the endoscopic ...

MINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), will present results from ...

Bringing finance, operational, and corporate development expertise to an experienced leadership team. MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ --Endogenex, Inc., a clinical-stage medical device company ...

Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes MINNEAPOLIS, March ...

MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it has closed an ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Plymouth, Minnesota-based ...